Contrast-induced nephropathy (CIN) is a well-known adverse event of therapeutic and diagnostic procedures requiring the adminstration of contrast medium (CM). The lack of a universal CIN definition and glomerular filtration rate markers that vary have resulted in a variety of reported incidences. The development of CIN is associated with an increase in the length of hospital stay and the risk of death. Preexisting renal dysfunction, age, diabetes, congestive heart failure and the volume of CM administered are all associated with a risk for developing CIN. The literature suggests the use of low-osmolarity CM and supports volume supplementation before administration. Moreover, other strategies to avoid CIN, including treatment with N-acetylcisteine and sodium bicarbonate have variable levels of evidence. This review examines the main components of the pathogenesis and risk factors of CIN and possible preventive measures and therapies.

Keywords:
Percutaneous coronary interventions, Iodinate contrast media, Contrast-induced nephropathy
1.
Ozcan EE, Guneri S, Akdeniz B, et al: Sodium bicarbonate, N-acetylcysteine and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J 2007;154:539-544.
2.
McCullough PA, Adam A, Becker CR, et al: CIN Consensus Working Panel. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006;98:5K-13K.
3.
Aspelin P, Aubry P, Fransson SG, et al: Nephrotoxicity in high risk patients undergoing angiography. N Engl J Med 2003;348:491-499.
4.
Briguori C, Airoldi F, D'Andrea D, et al: Renal insufficiency following contrast media administration trial (REMEDIAL). A randomized comparison of 3 preventive strategies. Circulation 2007;115:1211-1217.
5.
Fung JW, Szeto CC, Chan WW, et al: Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis 2004;43:801-808.
6.
Webb JG, Pate GE, Humpries KH, et al: A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 2004;148:422-429.
7.
Katzberg RW, Lamba R: Contrast-induced nephropathy after intravenous administration: fact or fiction? Radiol Clin North Am 2009;47:789-800.
8.
Bellomo R, Ronco C, Kellum JA, et al: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-R212.
9.
Kellum JA, Levin N, Bouman C, et al: Developing a consensus classification system for acute renal failure. Curr Opin Crit Care 2002;8:509-514.
10.
Vassalotti JA, Delgado FA, Whelton A: Atheroembolic renal disease. Am J Ther 1996;3:544-549.
11.
Hadhani RI, Camargo CA Jr, Xavier RJ, et al: Atheroembolic renal failure after invasive procedures: natural history based on 52 histologically proven cases. Medicine (Baltimore) 1995;74:350-358.
12.
Saklayen MG, Gupta S, Suryaprasad A, et al: Incidence of atheroembolic renal failure after coronary angiography - a prospective study. Angiology 1997;48:609-613.
13.
Hauben M, Norwich J, Shapiro E, et al: Multiple cholesterol emboli syndrome - six cases identified through the spontaneous reporting system. Angiology 1995;46:779-784.
14.
Reddan D, Laville M, Garovich VD: Contrast-induced nephropathy and its prevention: what do we really know from evidence-based findings? J Nephrol 2009;22:333-351.
15.
Weisbord SD, Mor MK, Resnick AL, Hartwig KC, Palevsky PM, Fine MJ: Incidence and outcomes of contrast-induced AKI following computed tomography. Clin J Am Soc Nephrol 2008;3:1274-1281.
16.
Kanbay M, Covic A, Coca SG, et al: Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 random trials. Int Urol Nephrol 2009;41:617-627.
17.
Solomon R: The role of osmolarity in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 2005;68:2256-2263.
18.
Bartholomew BA, Harjai KJ, Dukkipati S, et al: Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004;93:1515-1519.
19.
Nash K, Hafeez A, Hou S: Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-936.
20.
McCullough PA, Adam A, Becker CR, et al: CIN Consensus Working Panel. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006;98:27K-36K.
21.
Rihal CS, Textor SC, Grill DE, et al: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-2264.
22.
Freeman RV, O'Donnell M, Share D, et al; Blue Cross-Blue Shield of Michigan Cardiovascular Consortium (BMC2): Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002;90:1068-1073.
23.
Birck R, Krzossok S, Markowetz F, et al: Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003;362:598-603.
24.
Marenzi G, Lauri G, Assanelli E, et al: Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004;44:1780-1785.
25.
Sadeghi HM, Stone GW, Grines CL, et al: Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003;108:2769-2775.
26.
Lindsay J, Apple S, Pinnow EE, et al: Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv 2003;59:338-343.
27.
Dangas G, Iakovou I, Nikolsky E, et al: Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005;95:13-19.
28.
Braunwald E, et al (eds): Braunwald's Heart Disease: A Textbook of Cardiovacular Medicine, ed VII (Italian). Philadelphia, Saunders Elsevier, 2007, pp 2164-2168.
29.
McCullough PA, Soman SS, Shah SS, et al: Risk associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000;36:679-684.
30.
Szczech LA, Best PJ, Crowly E, et al; Bypass Angioplasty Revascularization Investigators (BARI): Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation 2002;105:2253-2258.
31.
Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998;339:799-805.
32.
McCullough PA: Why is chronic kidney disease the ‘spoiler' for cardiovascular outcomes? J Am Coll Cardiol 2003;41:725-728.
33.
Beattie JN, Soman SS, Sandberg KR, et al: Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 2001;37:1191-1200.
34.
Sica D: The implications of renal impairment among patients undergoing percutaneous coronary intervention. J Invasive Cardiol 2002;14(suppl B):30B-37B.
35.
Silverberg DS, Wexler D, Sheps D, et al: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron. J Am Coll Cardiol 2001;37:1775-1780.
36.
Friedman AN, Bostom AG, Selhub J, et al: The kidney and homocysteine metabolism. J Am Soc Nephrol 2001;12:2181-2189.
37.
Heyman SN, Rosen S, Khamaisi M, et al: Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Invest Radiol 2010;45:188-195.
38.
Heyman SN, Rosen S, Rosenberg C: Renal parenchymal hypoxia, hypoxia adaptation and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc Nephrol 2008;3:288-296.
39.
Clanton TL: Hypoxia-induced reactive oxygen species formation in skeletal muscle. J Appl Physiol 2007;102:2379-2388.
40.
Szeto HH: Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J 2006;8:E523-E531.
41.
Cracowski JL, Devillier P, Durand T, Stanke-Labesque F, Bessard G: Vascular biology of the isoprostanes. J Vasc Res 2001;38:93-103.
42.
Hsu YH, Chen JJ, Chang NC, Chen CH, Liu JC, Chen TH, Jeng CJ, Chao HH, Cheng TH: Role of reactive oxygen species-sensitive extracellular signal-regulated kinase pathway in angiotensin-II-induced endothelin-I gene expression in vascular endothelial cells. J Vasc Res 2004;41:64-74.
43.
Schnackemberg CG: Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am J Physiol Regul Integr Comp Physiol 2002;282:R335-R342.
44.
Sendenski M, Patzak A, Pallone TL, Cao C, Persson PB: Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy. Radiology 2009;251:697-704.
45.
Klause N, Arendt T, Lins M, Gronow G: Hypoxic renal tissue damage by endothelin-mediated arterial vasoconstriction during radioangiography in man. Adv Exp Med Biol 1998;454:225-234.
46.
Clark BA, Kim D, Epstein FH: Endothelin and atrial natriuretic peptide levels following radiocontrast exposure in humans. Am J Kidney Dis 1997;30:82-86.
47.
Louie EK, Al-Sadir J, Emmanouel D: Quantitative effects of osmotic diuresis following angiographic contrast administration. Cathet Cardiovasc Diagn 1986;12:235-239.
48.
Moreau JF, Droz D, Noe LH, Leibowitch J, Jungers P, Michel JR: Tubular nephrotoxicity of water-soluble iodinated contrast media. Invest Radiol 1980;15(6 suppl):S54-S60.
49.
Moreau JF, Droz D, Sabto J, Jungers P, Kleinknecht D, Hinglais N, Michel JR: Osmotic nephrosis induced by water-soluble triiodinated contrast media in man. A retrospective study of 47 cases. Radiology 1975;115:329-336.
50.
Tumlin JA, Wang A, Murray PT, Mathur VS: Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002;143:894-903.
51.
Rauch D, Drescher P, Pereira FJ, Knes JM, Will JA, Madsen PO: Comparison of iodinated contrast media. Induced renal vasoconstriction in human, rabbit, dog, and pig arteries. Invest Radiol 1997;32:315-319.
52.
Morris TW, Katezemberg RW, Fischer HW: A comparison of the hemodynamic responses to metrizamide and meglumine/sodium diatrozoate in canine renal angiography. Invest Radiol 1978;13:74-78.
53.
Bakris GL, Burnett JC Jr: A role for calcium in radiocontrast-induced reductions in renal hemodynamics. Kidney Int 1985;27:465-468.
54.
Nygren A: Contrast media and regional renal blood flow: a study of the effects of ionic and non-ionic monomeric and dimeric contrast media in the rat. Acta Radiol Suppl 1992;378:123-135.
55.
Palm F, Carlsson PO, Fasching A, Hellberg O, Nygren A, Hansell P, Liss P: Effects of the contrast medium iopromide on renal emodynamics and oxygen tension in the diabetic rat kidney. Adv Exp Med Biol 2003;530:653-659.
56.
Jakobsen JA: Renal effects of iodixanol in healthy volunteers and patients with severe renal failure. Acta Radiol Suppl 1995;399:191-195.
57.
Older RA, Korobkin M, Cleeve DM, Schaaf R, Thompson W: Contrast-induced acute renal failure: persistent nephrogram as clue to early detection. AJR Am J Roentgenol 1980;134:339-342.
58.
Love L, Johnson MS, Bresler Me, Nelso JE, Olson MC, Flisak ME: The persistent computed tomography nephrogram: its significance in the diagnosis of contrast-associated nephrotoxicity. Br J Radiol 1994;67:951-957.
59.
Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA; CIN Consensus Working Panel: Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006;98:14K-20K.
60.
Ribeiro L, de Assunção e Silva F, Kurihara RS, Schor N, Mieko E, Higa S: Evalutation of the nitric oxide production in rat renal artery smooth muscle cells culture exposed to radiocontrast agents. Kidney Int 2004;65:589-596.
61.
Kamdar A, Makoff DL, Massry SG: Acute renal failure (ARF) induced by radiographic contrast material (abstract). Clin Res 1976;24:128a.
62.
Swartz RD, Rubin JE, Leeming BW, Silva P: Renal failure following major angiography. Am J Med 1978;65:31-37.
63.
Chanard J, Jolly D, Doco JB, Bouquigny F, Wynckel A, Lacour P, Menanteau B, Elaerts J: Nephrotoxicity of conditional and low osmolarity radiocontrast media. J Nephrol 1991;4:203-209.
64.
Mehran R, Amyong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393-1399.
65.
Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, Hill JA, Winniford M, Cohen MB, VanFossen DB: Nephrotoxicity of ionic and non-ionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995;47:254-261.
66.
Mueller C, Buerkle G, Perruchoud AP, Buettner HJ: Female sex and risk of contrast nephropathy after percutaneous coronary intervention. Can J Cardiol 2004;20:505-509.
67.
Lindsay J, Apple S, Pinnow EE, Gevorkian N, Guberg L, Satler LF, Pichard AD, Kent KM, Suddath W, Waksman R: Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv 2003;59:338-343.
68.
Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, Lansky AJ, Tsounias E, Moses JW, Stone GW, Leon MB, Dangas GD: Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004;94:300-305.
69.
Turcot DB, Kiernan FJ, McKay RG, Grey NJ, Boden W, Predrizet GA: Acute hyperglycemia: implications for contrast-induced nephropathy during cardiac catheterization. Diabetes Care 2004;27:620-621.
70.
Nikolsky E, Mehran R, Lasic Z, Mintz GS, Lansky AJ, Na Y, Pocock S, Negoita M, Moussa I, Stone GW, et al: Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary intervention. Kidney Int 2005;67:706-713.
71.
McCullough PA, Bakris GL, Owen WF Jr, Klassen PS, Califf RM: Slowing the progression of diabetic nephropathy and its cardiovascular consequences. Am Heart J 2004;148:243-251.
72.
Briguori C, Marenzi G: Contrast-induced nephropathy: pharmacological prophylaxis. Kidney Int 2006;100:S30-S38.
73.
Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ, Moscucci M: Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005;118:843-849.
74.
Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, Youn TJ, Chung WY, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS: Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial - a randomized controlled study. Am Heart J 2008;155:499e1-499e8.
75.
Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F, Guozhen H, Yunfa J, Weili W, Shigiang L: Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2009;104:519-524.
76.
Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D'Ambrosio A, Montinaro A, Di Sciascio G: Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention [from the ARMYDA-CIN (Atorvastatin for Reduction of Myocardial Damage during Angioplasty-Contrast-Induced Nephropathy) trial]. Am J Cardiol 2011;108:1-7.
77.
Zhang BC, Li WM, Xu YW: High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol 2011;27:851-858.
78.
Lindsay J, Canos DA, Apple S, Pinnow E, Aggrey GK, Pichard AD: Causes of acute renal dysfunction after percutaneous coronary intervention and comparisons of late mortality rates with postprocedure rise of creatinine kinase-MB versus rise of serum creatinine. Am J Cardiol 2004;94:786-789.
79.
Cochran ST, Wong WS, Roe DJ: Predicting angiography-induced acute renal function impairment: clinical risk model. AJR Am J Roentgenol 1983;141:1027-1033.
80.
Alamartine E, Phayphet M, Thibaudin D, Barral FG, Veyret C: Contrast medium-induced acute renal failure and cholesterol embolism after radiological procedures: incidence risk factors and compliance with recommendations. Eur J Intern Med 2003;14:426-431.
81.
Louis BM, Hoch BS, Hernandez C, Namboodiri N, Neiderman G, Nissenbaum A, Foti FP, Magno A, Banayat G, Fata F, Manohar NL, Lipner HI: Protection from nephrotoxicity of contrast dye. Ren Fail 1996;18:639-646.
82.
Report of a WHO Scientific Group: Nutritional anemias. Geneva, World Health Organization, 1968.
83.
Levey AS, Bosch JP, Breyer-Lewis J, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. The Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
84.
National Kidney Foundation, K/DOQI: Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39(suppl 1):S1-S237.
85.
Mueller C, Buerkle G, Buettner HJ, et al: Prevention of contrast-media associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329.
86.
Solomon R, Werner C, Mann D, et al: Effects of saline, mannitol and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416.
87.
Stevens MA, McCullough PA, Tobin KJ, et al: A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the PRINCE study (Prevention of Radiocontrast-Induced Nephropathy Clinical Evaluation) J Am Coll Cardiol 1999;33:403.
88.
Manske CL, Sprafka JM, Strony JT, Wang Y: Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990;89:615.
89.
McCullough PA, Manley HJ: Prediction and prevention of contrast nephropathy. J Intervent Cardiol 2001;14:547.
90.
Stone GW, Tumlin JA, Madyoon H, et al: Design and rationale of CONTRAST - a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy. Rev Cardiovasc Med 2001;2(suppl 1):S31.
91.
Nevaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR: Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis 2009;53:617-627.
92.
Tepel M, van der Giet M, Schwarzfield C, Laufer U, Liermann D, Zidek W: Prevention of radiographic contrast agent induces reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
93.
Romano G, Briguori C, Quintavalle C, Zanca C, Rivera NV, Colombo A, Condorelli G: Contrast agents and renal cell apoptosis. Eur Heart J 2008;29:2569-2576.
94.
Diaz-Sandoval LJ, Kosowsky BD, Losordo DW: Acetylcysteine to prevent angiography related renal tissue injury (the APART trial). Am J Cardiol 2002;89:356-358.
95.
Shyu KG, Cheng JJ, Kuan P: Acetycysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002;40:1383-1388.
96.
Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF: Acetylcysteine for the prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003;289:553-558.
97.
Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J, Dutka P, Marzo K, Maesaka JK, Fishbane S: A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002;62:2202-2207.
98.
Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, Lepore S, Librera M, Villari B, Colombo A, Ricciardelli B: Acetylcysteine and contrast-agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40:298-303.
99.
Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK: Prospective randomized study of N-acetylcysteine, fenoldopam, and saline in the prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-283.
100.
Loutrianakis E, Stella D, Hussain A, Lewis B, Steen L, Sochanski M, Leya F, Grassman E: Randomized comparison of fenoldopam and N-acetylsysteine to saline in the prevention of radiocontrast nephropathy. J Am Coll Cardiol 2003;41(6s1):327A.
101.
Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ: A rapid protocol for the prevention of contrast induced renal dysfunction (RAPPID Study). J Am Coll Cardiol 2003;41:2114-2118.
102.
Goldenberg I, et al: Contrast-associated nephropathy and clinical outcome of patients with chronic renal insufficiency undergoing cardiac catheterization: lack of additive benefit of acetylcysteine to saline infusion. J Am Coll Cardiol 2003;41:537A.
103.
ACT Investigators: Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT). Circulation 2011;124:1250-1259.
104.
Sporer H, Lang F, Oberleithner H, Greger R, Deetjen P: Inefficacy of bicarbonate infusions on the course of postischaemic acute renal failure in the rat. Eur J Clin Invest 1981;11:311-315.
105.
Cohen G: The Fenton Reaction; in: Greenwald RA (ed): CRC Handbook of Methods for Oxygen Radical Research. Boca Raton, CRC Press, 1985, pp 55-64.
106.
Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, Norton HJ, Kennedy TP: Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;291:2328-2334.
107.
Efrati S, Berman S, Ilgiyeav I, Siman-Tov Y, Averbukh Z, Weissgarten J: Differential effects of N-acetylcyesteine. Theophylline or bicarbonate on contrast-induced rat renal vasoconstriction. Am J Nephrol 2009;29:181-191.
108.
Naidu KA: Vitamin C in human health and disease is still a mystery? An overview. Nutr J 2003;2:7.
109.
Leone AM, De Caterina AR, Sciahbasi A, Aurelio A, Basile E, Porto I, Trani C, Burzotta F, Niccoli G, Mongiardo R, Mazzari MA, Buffon A, Panocchia N, Romagnoli E, Lioy E, Rebuzzi AG, Crea F: Sodium bicarbonate plus N-acetylcisteine to prevent contrast-induced nephropathy in primary and rescue percutaneous coronary interventions: the BINARIO study. Eurointervention 2012;8:839-847.
110.
Mautone A, Brown JR: Contrast-induced nephropathy in patients undergoing elective and urgent procedures. J Interv Cardiol 2010;23:78-85.
111.
Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA, Tumlin J: CIN Consensus Working Panel. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006;98:59K-77K.
112.
Masuda, Yamada T, Mine T, Morita T, Tamaki S, Tsukamoto Y, Okuda K, Iwasaki Y, Hori M, Fukunami M: Comparison of usefulness of sodium-bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol 2007;100:781-786.
113.
Maioli M, Toso A, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Bellandi F: Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol 2008;52:559-604.
114.
Liistro F, Falsini G, Bolognese L: The clinical burden of contrast media-induced nephropathy. Ital Heart J 2003;4:668-676.
115.
Recio-Mayoral A, Chaparro M, Prado B, Còzar R, Mèndez I, Banerjee D, Kaski JC, Cubero J, Cruz JM: The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol 2007;49:1283-1288.
116.
Detrenis S, Meschi M, Musini S, Savazzi G: Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant 2005;20:1542-1550.
117.
Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC: Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008;148:284-294.
118.
Bagshaw SM, Ghali WA: Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Int Med 2005;165:1087-1093.
119.
McCullough PA: Contrast-induced acute kidney injury. J Am Coll Cardiol 2008;51:1419-1428.
120.
Bartorelli AL, Marenzi G: Contrast-induced nephropathy. J Intervent Cardiol 2008;21:4-85.
121.
Briguori C, Marenzi G: Contrast-induced nephropathy: pharmacological prophylaxis. Kidney Int 2006;69:S30-S38.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.